Martine Zimmermann

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer, has appointed Martine Zimmermann, PharmD, to its Board of Directors.

Zimmermann brings more than 30 years of international experience in regulatory affairs and quality management across multiple stages of drug development. Her expertise spans regulatory strategy, quality oversight and the development of pharmaceutical products across global markets.

She currently serves as Executive Vice President and Head of Regulatory Affairs, Quality and Alliance Management at Inventiva S.A. In this role, she oversees regulatory and quality functions while supporting strategic collaborations and alliance activities.

Previously, Zimmermann served as Senior Vice President and Head of Global Regulatory Affairs and R&D Quality at Ipsen Biopharmaceuticals. Earlier in her career, she spent more than 13 years at Alexion Pharma International, where she held several senior leadership positions in regulatory affairs.

Throughout her career, Zimmermann has worked across global drug development programs, contributing regulatory and quality expertise to support the advancement of pharmaceutical therapies through development and toward potential regulatory approval.

Her appointment adds extensive regulatory and quality experience to Candel Therapeutics’ Board as the company continues to advance its clinical-stage pipeline of multimodal immunotherapies. Candel is focused on developing therapies designed to stimulate and engage the immune system to address cancer and improve patient outcomes.

Zimmermann earned her Doctor of Pharmacy (PharmD) degree from the University of Strasbourg in France.